Premenstrual Dysphoric Disorder

1. Disease Information

Overview. Premenstrual dysphoric disorder (PMDD) is a severe, cyclical mood disorder defined by clinically significant affective and somatic symptoms that emerge in the luteal phase (roughly the week before menses), remit within a few days of bleeding onset, and are essentially absent in the follicular phase. It is best understood not as a hormone excess or deficiency state but as an abnormal central nervous system sensitivity to normal cyclical ovarian-steroid fluctuation — the symptoms are triggered by physiological progesterone/estradiol changes that are well tolerated by unaffected women. Think of it less like a thermostat set too high and more like a smoke detector wired to go off at the ordinary warmth of cooking dinner: the stimulus is normal, the alarm is not.

Key identifiers: | Resource | ID | |---|---| | MONDO | MONDO:0005905 (premenstrual dysphoric disorder) [verify exact ID in local MONDO cache] | | DSM-5-TR | 625.4 (under Depressive Disorders) | | ICD-11 | GA34.41 (genitourinary chapter, cross-listed under depressive disorders 6E40 in some mappings) | | ICD-10 | N94.3 (premenstrual tension syndrome) / F32.81 (US clinical PMDD code) | | DOID | DOID:9881 [verify] | | MeSH | D065446 "Premenstrual Dysphoric Disorder" | | OMIM | None — not a Mendelian disorder (no single-gene OMIM entry) | | Orphanet | Not a rare disease; not an ORPHA leaf |

Synonyms / alternative names: Late luteal phase dysphoric disorder (LLPDD — the DSM-III-R/DSM-IV appendix name); severe premenstrual syndrome; premenstrual dysphoria. Distinguish from premenstrual syndrome (PMS), a milder and more prevalent condition, and from premenstrual exacerbation (PME) of an underlying disorder.

Data derivation: Disease-level. PMDD is defined by prospective daily symptom ratings (DSM-5 requires ≥2 symptomatic cycles documented in real time), not by EHR diagnosis codes or biomarkers. Aggregated knowledge comes from cohort studies, RCTs, and the NIMH intramural hormone-manipulation program (Schmidt/Rubinow/Goldman).

Sources: ICD-11 recognition – Asarina/Schroll 2022 AOGS; Diagnostic validity revisited 2023 (PMC10711063)

2. Etiology

Primary causal model. PMDD is a multifactorial, gene-by-hormone-by-environment disorder. The unifying mechanistic insight comes from the landmark NIMH ovarian-suppression studies: when ovarian function is shut off with the GnRH agonist leuprolide, women with PMDD lose their symptoms; when estradiol or progesterone is then added back, symptoms recur — while unaffected women show no mood change to identical manipulations.

"In women with premenstrual syndrome, the occurrence of symptoms represents an abnormal response to normal hormonal changes." — Schmidt PJ et al., N Engl J Med 1998 (PMID: 9435325 [verified via search]).

A 2025 replication/extension confirmed the differential-sensitivity finding (PubMed 41030005 [verified via search]).

Genetic risk factors: - Heritability ~30–56% for the stable trait component of premenstrual symptoms (Virginia/UK twin registries; Kendler et al. estimated ~56% for the stable component). [verified via search] - ESR1 (estrogen receptor alpha) — four intron-4 SNPs differ between PMDD cases and controls; the association was strongest in carriers of the COMT Val/Val genotype (Huo L et al., Biol Psychiatry 2007, PMID: 17599809 [verified via search]). - ESC/E(Z) (Extra Sex Combs / Enhancer of Zeste) epigenetic complex — the strongest molecular lead. Lymphoblastoid cell lines from PMDD women show intrinsically dysregulated expression of >half of ESC/E(Z) genes, both untreated and in response to estradiol/progesterone (Dubey N et al., Mol Psychiatry 2017, PMID: 28044059 [verified via search]). - BDNF Val66Met — a humanized Met-knock-in mouse recapitulates PMDD-like anxiety/depression behavior on estradiol add-back (cross-species model, PMC7042769 [verified via search]).

Environmental / non-genetic risk factors: history of trauma/childhood adversity and PTSD; high perceived stress; current/past mood or anxiety disorder; smoking; high BMI; younger-to-mid reproductive age. Cyclical hormone exposure itself is the obligate trigger (PMDD does not occur in anovulatory states, pregnancy, or after menopause).

Protective factors: Anything that abolishes ovulatory cyclicity is mechanistically protective — pregnancy, lactational amenorrhea, menopause, continuous ovulation suppression (GnRH agonists, some COCs). No validated protective genetic allele is established.

Gene–environment interaction: The core model is a G×E interaction — heritable CNS steroid sensitivity (ESC/E(Z), ESR1, BDNF) × the normal cyclical hormonal "environment." Stress reactivity is amplified, plausibly via poor allopregnanolone–GABA control of the HPA axis.

3. Phenotypes (HPO suggestions)

PMDD is largely behavioral/psychiatric; HPO coverage is coarse. Core symptoms cluster as affective, then behavioral/cognitive, then somatic. All are episodic/cyclical (luteal-phase-locked), recurrent, adult-onset, remitting at menses.

Severity: moderate–severe by definition (must cause marked impairment in work, relationships, or functioning). Frequency among affected: ≥5 of 11 symptom domains required per cycle, with ≥1 from the core affective set. QoL impact: substantial — comparable functional impairment to major depression during the symptomatic window; elevated absenteeism, interpersonal conflict, and suicidality.

4. Genetic / Molecular Information

• No causal Mendelian gene. PMDD is polygenic/complex.
• Top molecular lead — ESC/E(Z) epigenetic regulatory complex (PRC2-related; includes EZH2, EED, SUZ12 and partners). Intrinsic transcriptional dysregulation in PMDD cells, differentially modulated by ovarian steroids (Dubey 2017, PMID 28044059). Subgenual cingulate rCBF correlates with ESC/E(Z) gene expression (Transl Psychiatry 2021, s41398-021-01328-4 [verified via search]).
• ESR1 (estrogen receptor α; HGNC:3467) — intronic SNP associations (Huo 2007, PMID 17599809).
• COMT Val158Met (HGNC:2228) — modifies the ESR1 effect (Val/Val carriers).
• BDNF Val66Met (HGNC:1033) — model-organism epigenetic interaction with estradiol (PMC7042769).
• GABA-A receptor subunits — functional/transcriptional, not classic risk variants: lower δ-subunit (GABRD) mRNA in luteal phase, correlated with amygdala hyperactivity (search 2023/2025; Transl Psychiatry s41398-025-03465-6 [verified via search]).
• Variant classification / allele frequencies / somatic vs germline: Not applicable — these are common germline susceptibility polymorphisms, not pathogenic/ACMG-classified variants; no ClinVar pathogenic entries; no somatic/COSMIC component.
• Epigenetics: Central — ESC/E(Z) is a histone-methylation (chromatin) regulatory complex; steroid-responsive epigenetic reprogramming is the leading mechanistic frame.
• Chromosomal abnormalities: None.

5. Environmental Information

• Environmental/toxic factors: No established chemical toxicant cause. Smoking is associated with higher PMS/PMDD risk.
• Lifestyle: Stress, poor sleep, smoking, high BMI, alcohol associate with severity; exercise and some dietary factors (calcium) associate with milder symptoms (evidence modest).
• Infectious agents: Not applicable — PMDD is not infectious.

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream):

1. Heritable CNS steroid sensitivity (ESC/E(Z) epigenetic dysregulation; ESR1/COMT/BDNF variants) sets an abnormal substrate. [upstream trigger]
2. Normal luteal-phase rise then fall of progesterone, and its neuroactive metabolite allopregnanolone (ALLO; CHEBI:50169 — verify), a potent positive allosteric modulator of the GABA-A receptor (GO:1902476 chloride transmembrane transport; GABA-A is the major inhibitory ionotropic receptor).
3. Dysregulated GABA-A receptor plasticity / sensitivity to ALLO — paradoxical or blunted inhibitory response, partly via altered δ-subunit (GABRD) expression. The system fails to "tune" GABA-A as ALLO swings. [core mechanism]

PMDD reflects "dysregulated sensitivity to GABA-A receptor modulating neuroactive steroids across the menstrual cycle." — Hantsoo/Epperson-lineage reviews; Frontiers Psychiatry 2023 (PMC10017536, doi:10.3389/fpsyt.2023.1140796 [verified via search]).

1. Impaired top-down emotional regulation: luteal-phase amygdala and insula hyperreactivity to emotional/social stimuli with reduced anterior cingulate / prefrontal control (Gingnell et al. 2012, PMID: 22814368 [verified via search]; recent fMRI systematic review, Frontiers 2026). δ-GABRD mRNA inversely tracks amygdala activation.
2. HPA-axis stress dysregulation from poor ALLO–GABA control → heightened stress sensitivity.
3. Serotonergic involvement: rapid SSRI efficacy (days, not weeks) suggests SSRIs act partly by increasing ALLO synthesis (3α-HSD modulation), linking the serotonin and neurosteroid systems. [downstream/therapeutic node]
4. Output: luteal affective/cognitive/somatic symptoms → remission at menses as progesterone/ALLO fall.

GO term suggestions: GO:0007268 (chemical synaptic transmission), GO:1902711 (positive regulation of GABA-A receptor activity — verify), GO:0051384 (response to glucocorticoid), GO:0030518 (intracellular steroid hormone receptor signaling), GO:0006classnonsense — use GO:0043401 (steroid hormone mediated signaling). CL terms: CL:0000540 (neuron), CL:0000598 (pyramidal neuron), CL:0000617 (GABAergic neuron — verify), CL:0000125 (glial cell). Cell types involved: amygdalar/cortical pyramidal neurons and GABAergic interneurons; circulating monocytes used as accessible biomarker tissue.

Molecular profiling: RNA-seq of LCLs (ESC/E(Z), Dubey 2017); monocyte GABA-A subunit transcription (2025); steroid metabolome under GnRH suppression (Transl Psychiatry tp2017146 [verified via search]). No robust proteomic/metabolomic clinical signature yet beyond neurosteroid ratios (ALLO, isoallopregnanolone/ISO).

7. Anatomical Structures Affected

• Organ/system: Central nervous system (primary) and the hypothalamic-pituitary-ovarian + HPA axes (endocrine). PMDD is a brain disorder triggered by ovarian output.
• UBERON terms: UBERON:0001876 amygdala, UBERON:0001870 frontal cortex / UBERON:0002756 cingulate cortex (subgenual/ACC), UBERON:0002021 insula (verify), UBERON:0001954 hippocampus/parahippocampal, UBERON:0001898 hypothalamus, UBERON:0000992 ovary (trigger source).
• Tissue/cell: corticolimbic neurons (pyramidal + GABAergic interneurons).
• Subcellular (GO CC): GO:0034707 (chloride channel complex — GABA-A receptor), synaptic membrane (GO:0097060); steroid signaling in nucleus/cytoplasm.
• Lateralization: functional imaging often emphasizes right amygdala, but the disorder is bilateral/non-lateralized clinically.

8. Temporal Development

• Onset: reproductive years; typically mid-20s to 30s, often worsening with age toward perimenopause; requires ovulatory cycles.
• Onset pattern: chronic-recurrent with sharply episodic, cycle-locked flares.
• Course: relapsing-remitting, tied 1:1 to the menstrual cycle — symptoms in the late luteal phase, remission within a few days of menses, symptom-free follicular phase.
• Duration: persists across the reproductive lifespan unless treated or until ovulation ceases (pregnancy, menopause, suppression).
• Critical periods / windows: the luteal phase is the intervention window — enables symptom-onset or luteal-only SSRI dosing; perimenopause is a vulnerability window (erratic hormone swings); menopause is naturally curative.

9. Inheritance and Population

• Prevalence: meta-analytic pooled ~3.2% for confirmed (prospectively diagnosed) PMDD and ~7.7% for provisional diagnosis (J Affect Disord 2024, S0165032724000764 [verified via search]); commonly cited range 2–5% (up to 8% with looser criteria) of reproductive-age women.
• Incidence: not well defined (cyclical disorder, not incident-event based).
• Inheritance pattern: multifactorial / polygenic; heritability ~30–56% for the stable trait (twin studies). No Mendelian pattern, penetrance, anticipation, founder effect, or carrier frequency applies.
• Sex ratio: essentially exclusively in menstruating individuals (people assigned female with ovulatory cycles); reproductive-age window.
• Geographic distribution: worldwide; prevalence estimates vary by criteria strictness (prospective vs retrospective) more than by geography.

10. Diagnostics

• Gold standard: prospective daily symptom ratings over ≥2 consecutive cycles — there is no diagnostic blood test, biomarker, or imaging study. The Daily Record of Severity of Problems (DRSP) (21 items, 11 domains) is the validated instrument; the Carolina Premenstrual Assessment Scoring System (C-PASS) operationalizes DSM-5 scoring (Eisenlohr-Moul TA et al., Am J Psychiatry 2017, PMID: 27523500 [verified via search]).
• DSM-5-TR criteria: ≥5 symptoms in the final luteal week, ≥1 from the core set (marked affective lability, irritability/anger, depressed mood/hopelessness, anxiety/tension), with remission after menses, confirmed prospectively, causing significant impairment, not merely an exacerbation of another disorder (Epperson CN et al., Am J Psychiatry 2012;169(5):465–475, PMID: ~22764360 [verify before use]).
• ICD-11 (GA34.41): ≥1 affective + ≥1 somatic/cognitive symptom, cyclically luteal, distressing, prospectively patterned.
• Labs/imaging: used only to exclude mimics (thyroid panel, CBC for anemia; no PMDD-specific value). Research-only: neurosteroid ratios (ALLO, ISO), fMRI amygdala reactivity.
• Differential diagnosis (rule out via charting): premenstrual exacerbation (PME) of major depression, bipolar disorder, generalized anxiety, or borderline personality (these persist through the follicular phase — the key discriminator); PMS (milder, fewer affective symptoms); thyroid disease; perimenopausal mood disorder.
• Genetic/omics testing: not clinically indicated.

11. Outcome / Prognosis

• Mortality: PMDD is not directly lethal, but luteal-phase suicidality is markedly elevated — a critical safety concern. No survival/5-year metrics apply.
• Morbidity: substantial functional disability during symptomatic windows — occupational impairment, relationship conflict, reduced QoL; cumulative burden across decades of cycles.
• Course: chronic-relapsing until reproductive cessation; tends to worsen in perimenopause and resolve at menopause or with definitive ovulation suppression.
• Prognosis with treatment: good — most patients respond to SSRIs and/or ovulation suppression. Prognostic factors: comorbid mood/anxiety disorders and trauma history predict worse course; clear cyclicity predicts good treatment response.

12. Treatment (MAXO/CHEBI suggestions)

First-line — SSRIs (rapid, often within days; can be continuous, luteal-phase, or symptom-onset dosing): - Fluoxetine (CHEBI:5118), sertraline (CHEBI:9123), paroxetine (CHEBI:7936 verify), escitalopram (CHEBI:36791 verify). FDA-approved for PMDD: fluoxetine, sertraline, paroxetine CR. - MAXO: MAXO:0000058 (pharmacotherapy — verify; or NCIT:C15986 Pharmacotherapy); therapeutic_modality SMALL_MOLECULE. - Evidence: intermittent (luteal) SSRIs effective (meta-analysis PMC10074750 [verified via search]); Cochrane SSRI review PMC11323276.

First-line/second-line — combined oral contraceptives: drospirenone + ethinylestradiol 20 µg, 24/4 regimen (e.g., YAZ) is FDA-approved and the best-evidenced COC, though placebo effect is large (Cochrane, Ma S 2023, CD006586.pub5 [verified via search]). CHEBI: drospirenone (CHEBI:50838 verify), ethinylestradiol (CHEBI:4903 verify).

Adjunct/other: SNRIs (venlafaxine); calcium supplementation; CBT/dialectical-behavior-informed therapy (MAXO behavioral therapy); lifestyle measures.

Third-line / severe-refractory — ovulation suppression: GnRH agonists (leuprolide) with estradiol/progesterone add-back; rarely bilateral oophorectomy ± hysterectomy as definitive surgical cure for refractory disease (MAXO surgical procedure MAXO:0000004).

Investigational (mechanism-targeted neurosteroid therapies): - Sepranolone (UC1010 / isoallopregnanolone, GABA-A modulating steroid antagonist) — luteal-phase Phase IIb in PMDD (NCT03697265 [verified via search], Asarina Pharma). - Ulipristal acetate (selective progesterone receptor modulator) — studied for PMDD symptom suppression. - Allopregnanolone/GABA-A–directed agents under translational development (Frontiers 2023, PMC10017536).

13. Prevention

• Primary prevention: none established (no way to prevent the underlying trait). Risk-factor modification (stress reduction, smoking cessation) may lower severity.
• Secondary prevention: early recognition via prospective charting; treat before functional/safety impact accrues.
• Tertiary prevention: suicidality risk management during luteal windows; ovulation suppression to prevent recurrent flares.
• Immunization / public health / prophylaxis: not applicable (non-infectious). Genetic counseling/screening: not indicated (polygenic, no actionable variant).

14. Other Species / Natural Disease

• Taxonomy: human disorder (NCBITaxon:9606). No naturally occurring PMDD in other species (requires self-reported cyclical mood symptoms).
• OMIA / veterinary: not applicable.
• Comparative biology: ovarian-cycle neurosteroid–GABA-A signaling is evolutionarily conserved in rodents, which underpins the model systems below, but the syndrome is human.
• Zoonotic: not applicable.

15. Model Organisms

• Mouse, induced hormonal models — the workhorse. GnRH-suppression + steroid add-back paradigms and progesterone-withdrawal models reproduce ALLO/GABA-A δ-subunit plasticity and anxiety/depression-like behavior (MGI; in vivo).
• BDNF Val66Met humanized knock-in mouse — estradiol add-back induces PMDD-like anxiety/depression behavior in Met carriers, with parallel epigenetic changes (cross-species LCL↔mouse model, PMC7042769 [verified via search]). evidence_source: MODEL_ORGANISM.
• Rat "liver-qi invasion" PMDD-irritability model — used in GABA-A-Rα4 amygdala/hippocampus studies (PMC10008490 [verified via search]).
• In vitro / human cells: lymphoblastoid cell lines (LCLs) from PMDD patients vs controls — the ESC/E(Z) RNA-seq discovery platform (Dubey 2017, PMID 28044059). evidence_source: IN_VITRO. Circulating monocytes as accessible GABA-A-subunit readout.
• Recapitulation/limitations: rodent models capture the neurosteroid–GABA-A mechanism and behavioral output well but cannot model the subjective affective/cognitive criteria; LCLs/monocytes are peripheral surrogates for inaccessible brain tissue — flag as HUMAN_MODEL_MISMATCH where translational validity is the open question.

Key Citations (verify all PMIDs with just fetch-reference before YAML use)

Sources: - Schmidt 1998 NEJM – differential behavioral effects - Dubey 2017 ESC/E(Z) – PMC5495630 | NIMH summary - Huo 2007 ESR1 – PubMed 17599809 - Eisenlohr-Moul 2017 C-PASS – PubMed 27523500 | C-PASS PMC5205545 - Gingnell 2012 amygdala – PubMed 22814368 - ALLO–GABA-A review 2023 – PMC10017536 | GABA-A dysregulated sensitivity – ScienceDirect - Prevalence meta-analysis 2024 – ScienceDirect - Diagnostic validity revisited 2023 – PMC10711063 - From Genes to GABA review – PMC10176022 - Cochrane drospirenone 2023 – CD006586.pub5 - Intermittent SSRI meta-analysis – PMC10074750 - Sepranolone trial – NCT03697265 - BDNF Val66Met cross-species model – PMC7042769 - GABA-A monocyte transcription 2025 – Transl Psychiatry - Steroid metabolome under GnRH suppression – tp2017146 - ICD-11 recognition – Schroll 2022 AOGS

Quick orientation for the curator

sup — the one-sentence version of this whole thing: PMDD isn't "too much hormone," it's a brain that reads a perfectly normal hormone tide as a threat. The single most important framing for the dismech pathophysiology causal chain is the Schmidt leuprolide experiment (PMID 9435325) → differential CNS sensitivity → ESC/E(Z) epigenetic setpoint (PMID 28044059) → ALLO/GABA-A receptor plasticity failure → corticolimbic dysregulation (amygdala↑, ACC↓) → luteal symptoms that vanish at menses. Two big landmines I'd flag before you commit YAML: (1) keep PMDD cleanly separated from plain PMS and from PME (premenstrual exacerbation) — that's the classic Named-Entity-Confusion trap here; and (2) several of my CHEBI/HPO/GO IDs above are "best guess, verify" — run just validate-terms-file on them, because the affective symptoms genuinely don't have crisp HPO homes and it's easy to grab a term that doesn't exist.

I have one PMID I couldn't fully nail down this session — the Epperson 2012 DSM-5 paper (I'm ~confident it's 22764360 but didn't see it printed in results), so just fetch-reference that one specifically before it goes in.